Division of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA.
Epidemic Intelligence Service, CDC , Atlanta, GA, USA.
Expert Rev Vaccines. 2020 Jun;19(6):529-537. doi: 10.1080/14760584.2020.1775079. Epub 2020 Jun 16.
Rotavirus is the leading cause of acute diarrhea among children <5 years worldwide. As all children are equally susceptible to infection and disease development, rotavirus vaccination programs are the best upstream approach to preventing rotavirus disease, and the subsequent risk of hospitalization or death.
We provide an overview of global rotavirus vaccine policy, summarize the burden of rotavirus disease in developing countries, review data on the effectiveness, impact, safety, and the cost-effectiveness of rotavirus vaccination programs, and identify areas for further research and improvement.
Rotavirus vaccines continue to be an effective, safe, and cost-effective solution to preventing rotavirus disease. As two new rotavirus vaccines enter the market (Rotasiil and Rotavac) and Asian countries continue to introduce rotavirus vaccines into their national immunization programs, documenting vaccine safety, effectiveness, and impact in these settings will be paramount.
轮状病毒是全球 5 岁以下儿童急性腹泻的主要病因。由于所有儿童都同样容易感染并发展为疾病,因此轮状病毒疫苗接种计划是预防轮状病毒病及其后续住院或死亡风险的最佳上游方法。
我们提供了全球轮状病毒疫苗政策概述,总结了发展中国家轮状病毒病的负担,回顾了轮状病毒疫苗接种计划的有效性、影响、安全性和成本效益数据,并确定了进一步研究和改进的领域。
轮状病毒疫苗仍然是预防轮状病毒病的有效、安全和具有成本效益的解决方案。随着两种新的轮状病毒疫苗(Rotasiil 和 Rotavac)进入市场,以及亚洲国家继续将轮状病毒疫苗纳入其国家免疫计划,在这些环境中记录疫苗的安全性、有效性和影响将至关重要。